Elevance Health, Inc. which can be found using ticker (ELV) have now 17 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $665.00 and $558.00 suggesting an average Analsyt target price of $605.45. Given that the stocks previous close was at $539.99 and the analysts are correct then there would likely be a percentage uptick in value of 12.1%. The 50 day MA is $519.36 and the 200 day moving average is $481.71. The company has a market capitalization of 126.41B. The stock price for the company is currently $543.89 USD
The potential market cap would be $141,733,790,136 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.53, revenue per share of $731.76 and a 5.78% return on assets.
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
